ReviewBiomedicines2021
Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07013123 (Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Pooled it
- Epithelial alarmins TSLP, IL-33, and IL-25 in asthma pathogenesis: mechanistic roles and therapeutic implications.Molecular biology reports · 2026Review
- Systemic Immune Dysregulation in Allergic Rhinitis: Mechanisms, Comorbidities, and Implications for Targeted Therapy.Journal of asthma and allergy · 2026Review
- The airway epithelial-immune axis: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
- Biologic Therapy in Severe Asthma: A Phenotype-Driven and Targeted Approach.Journal of clinical medicine · 2025Review
- Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis.International journal of molecular sciences · 2025Review
- Targeting alarmins in asthma: From bench to clinic.The Journal of allergy and clinical immunology · 2025Review
- Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma.Frontiers in allergy · 2025Review
- Personalized COPD Care: The Future of Precision-Based Therapies.Journal of clinical medicine · 2024Review
- Body Weight and Allergic Asthma: A Narrative Review.Journal of clinical medicine · 2024Review
- Review
- Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis.The World Allergy Organization journal · 2024Article
- Airway Epithelial-Derived Immune Mediators in COVID-19.Viruses · 2023Review
- Switching Biological Therapies in Severe Asthma.International journal of molecular sciences · 2023Review
- Potential Role of Innate Lymphoid Cells in the Pathogenesis and Treatment of Skin Diseases.Journal of clinical medicine · 2023Review
- Special Issue on 'Asthma and Allergic Inflammation'.Vaccines · 2023Article
- Beyond allergic progression: From molecules to microbes as barrier modulators in the gut-lung axis functionality.Frontiers in allergy · 2023Review
- Louki Zupa decoction attenuates the airway inflammation in acute asthma mice induced by ovalbumin through IL-33/ST2-NF-κB/GSK3β/mTOR signalling pathway.Pharmaceutical biology · 2022Article
- Clinical implications of asthma endotypes and phenotypes.Allergy and asthma proceedings · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alarmins are innate cytokines, including thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25), which are mainly produced by airway epithelium and exert a prominent role in asthma pathobiology. In particular, several environmental factors such as allergens, cigarette smoking, airborne pollutants, and infectious agents trigger the release of alarmins, which in turn act as upstream activators of pro-inflammatory pathways underlying type 2 (T2-high) asthma. Indeed, alarmins directly activate group 2 innate lymphoid cells (ILC2), eosinophils, basophils, and mast cells and also stimulate dendritic cells to drive the commitment of naïve T helper (Th) cells towards the Th2 immunophenotype. Therefore, TSLP, IL-33, and IL-25 represent suitable targets for add-on therapies of severe asthma. Within this context, the fully human anti-TSLP monoclonal antibody tezepelumab has been evaluated in very promising randomized clinical trials. Tezepelumab and other anti-alarmins are thus likely to become, in the near future, valuable therapeutic options for the biological treatment of uncontrolled severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.